Status:
UNKNOWN
Anti IL6R Reduce Complement Serum Level in Rheumatoid Arthritis Patients: Facts and Implications
Lead Sponsor:
BADOT, Valerie
Conditions:
Rheumatoid Polyarthritis
Eligibility:
All Genders
18+ years
Brief Summary
Interleukin 6 is identified as a cytokine with pro and anti-inflammatory effects, depending on the context to which it is exposed, exerting a role in the expansion and activation of T lymphocytes, in ...
Eligibility Criteria
Inclusion
- Patient ≥ 18 years old
- Regular follow-up at CHU Brugmann Hospital for confirmed rheumatoid arthritis and meeting the ACR 2010 criteria
- On tocilizumab / sarilumab or for which this treatment is about to be initiated, in intravenous or subcutaneous form
Exclusion
- Patients with a known complement deficiency before their rheumatic pathology
- Patient with hepatic impairment
Key Trial Info
Start Date :
July 14 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT04505982
Start Date
July 14 2020
End Date
December 1 2020
Last Update
August 10 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brugmann University Hospital
Brussels, Belgium, 1020